Globe Newswire (Wed, 18-Mar 8:30 AM ET)
Trinity Biotech Targets Diabetes Growth With CGM Push and Brazil HbA1c Rollout
TipRanks (Mon, 16-Mar 11:57 AM ET)
Globe Newswire (Thu, 12-Mar 9:00 AM ET)
Globe Newswire (Wed, 11-Mar 9:00 AM ET)
Globe Newswire (Tue, 10-Mar 7:55 AM ET)
Trinity Biotech Provides Business and Trading Update
Globe Newswire (Tue, 10-Mar 7:45 AM ET)
Trinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives
Globe Newswire (Wed, 25-Feb 9:00 AM ET)
Globe Newswire (Fri, 20-Feb 5:00 PM ET)
Globe Newswire (Fri, 13-Feb 5:00 PM ET)
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
Trinity Biotech PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol TRIB.
As of March 20, 2026, TRIB stock price declined to $0.64 with 102,913 million shares trading.
TRIB has a beta of 2.83, meaning it tends to be more sensitive to market movements. TRIB has a correlation of 0.20 to the broad based SPY ETF.
TRIB has a market cap of $12.03 million. This is considered a Sub-Micro Cap stock.
Last quarter Trinity Biotech PLC - American Depositary Shares reported $11 million in Revenue and -$.32 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.12.
In the last 3 years, TRIB traded as high as $6.20 and as low as $.48.
TRIB has underperformed the market in the last year with a price return of -3.5% while the SPY ETF gained +15.6%. TRIB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -29.3% and -13.0%, respectively, while the SPY returned -4.7% and -4.8%, respectively.
TRIB support price is $.60 and resistance is $.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TRIB shares will trade within this expected range on the day.